Prime Business Africa
Four majority investors in the pharmaceutical companies listed on the Nigerian Exchange (NGX) recorded a combined gain of N52.61 billion in the first quarter (Q1) of 2026, according to Prime Business Africa’s (PBA) analysis.
Also, two majority investors recorded a combined loss of N4.16 billion during the period under review.
This indicates that four pharmaceutical companies recorded an appreciation in their shares during trading in the Nigerian stock market between January and March of this year, while two experienced a decline.
Join our WhatsApp ChannelMajor Investors With Highest Increase In Investments
Charles Osezua/Morison
Charles Osezua, a director and major investor in Morison, recorded a 129.12 percent growth in his investment in the company in the first quarter of 2026, after the share price of the drugmaker increased by N6.65 kobo.
- At the start of the quarter, traders exchanged a share of Morison at N5.15 kobo, however, by the end of March, the value of the share increased significantly to N11.80 kobo.
- This raised the investment value of Osezua, who holds 201.72 million shares or a 16 percent stake in Morison, from N1.03 billion at the start of January to N2.38 billion at the end of the first quarter, representing a N1.34 billion gain for the director.
- According to an analysis of the investment held by Osezua, the increase in the value of his shares, which presents a 16.06 percent stake, is the highest among the major investors in the pharmaceutical companies listed on the NGX.
TY Danjuma/May and Baker
Theophilus Yakubu Danjuma, popularly known as TY Danjuma, is the major shareholder in May and Baker, where he holds 720.87 million shares, representing a 41.78 percent stake, through T.Y Holdings, his investment vehicle.
- Analysis showed that Danjuma’s investment was the second best-performing investment held by a major investor in the pharmaceutical companies on the NGX, as the businessman recorded 100 percent growth
- His investment increased by a whopping N13.69 billion between January and March this year, after the value of his shares surged to N27.39 billion as of March 31, exceeding the N13.69 billion they were worth on January 2.
- The surge was on the back of a N19 gain by the shares of May and Baker, which increased from N19 per share at the start of this year to N38 per share at the end of March.
Fidelis Ayebae/Fidson Healthcare
The investment of Fidelis Ayebae, the founder and majority investor in Fidson Healthcare, appreciated by 81.81 percent in the first three months of 2026, making his investment the third highest increase among his peers.
- It was gathered that the appreciation in Ayebae’s investment represents N34.13 billion in monetary terms, and this was driven by a N45 kobo increase in Fidson’s share price during the period under review.
- At the start of the year, equity traders in the stock market were willing to buy a share of Fidson at N55, however, their offering price skyrocketed twofold to N100 by the end of the first quarter.
- This impacted the value of Ayebae’s shares — which were 758.54 million and represent a 31.61 percent stake — as their worth jumped to N75.85 billion at the end of March, compared to the N41.71 billion recorded on March 31.
Christopher Oshiafi/Damitop Consulting Limited/Neimeth
The value of 820.04 million shares held by Damitop Consulting Limited, led by Christopher Oshiafi, in Neimeth International Pharmaceutical, increased by N3.44 billion to N8.28 billion at the end of the first quarter.
- According to PBA’s analysis, the value of the shares, which represents a 19.19 percent stake, increased from the N4.83 billion they were worth at the start of the period under review, indicating a 71.18 percent growth.
- The double-digit increase was the fourth highest appreciation when compared to other major investors’ investment growth, and this was made possible by a N4.2 kobo jump in Neimeth’s share price.
- The price surged to N10.10 kobo per share at the end of March, compared to the N5.90 kobo stock market investors were willing to pay for a share of the pharmaceutical company at the start of the first quarter.
Major Investors With Investment Decline
Midas Investment & Properties Limited/Juli Plc
Midas Investment & Properties Limited was not as lucky as the aforementioned major shareholders, as the company’s investment in Juli Plc declined by 9.92 percent, after a N0.8 kobo drop in the share price of Juli.
- The major investor, which holds 151.65 million shares, representing a 28.45 percent stake, in Juli, saw its investment value decline to N1.10 billion on March 31, below the N1.22 billion they were worth on January 2.
- According to Juli’s NGX performance data, Midas lost N121.32 million in its investment after the share price of the former decreased to N7.26 kobo at the end of Q1, failing to surpass the N8.06 per share reported at the beginning of this year.
Samir Udani/MeCure
Samir Udani, the chairman of MeCure and major investor, saw his investment in the pharmaceutical company decline by N4.03 billion within three months, according to analysis of MeCure’s share performance.
- The loss recorded by Udani followed a N3.7 kobo decline in the share price of MeCure, as equity traders in the stock market traded a share of the company at N65.20 kobo on March 31, compared to N65.20 kobo on January 2.
- Prime Business Africa gathered that the N3.7 kobo decline in MeCure’s share price led to Udani’s investment in the pharmaceutical company decreasing by 5.67 percent in the first three months of 2026.
- Consequently, the value of Udani’s shares in MeCure, which is 1.09 billion and represents a 27.29 percent stake, dropped from N71.18 billion to N67.14 billion within the first quarter.
Meanwhile, May and Baker led the list of the best-performing pharmaceutical companies by profit growth in 2025, while Juli topped the list of the worst-performing.
For press releases, tip-offs, and corporate information, call 08149575257 (hotline), email: [email protected] and [email protected]
Prime Business Africa is a business, economy and policy news platform founded in 2021 by veteran journalist and media scholar, Dr Marcel Mbamalu, after he left The Guardian as Editor.
Dr Mbamalu, who serves as Founder and Publisher, set up Prime Business Africa to deliver sharp, data-driven reporting on Nigeria’s markets, trade, investment, and governance trends for decision-makers, entrepreneurs, and policy leaders.
He also writes The Bottom Line, a backpage column for Punch Newspaper every Thursday.
Under his leadership, Prime Business Africa combines deep newsroom experience with a focus on accountability journalism, aiming to bridge information gaps between Africa’s private sector and the global economy.
